Esperion Therapeutics Inc (ESPR)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Esperion Therapeutics Inc (ESPR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014041
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:49
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Esperion Therapeutics Inc (Esperion) is a pharmaceutical company that develops and commercializes oral therapies to treat patients with elevated low-density lipoprotein cholesterol (LDL-C). The company’s lead product candidate, Bempedoic acid, an ATP-citrate lyase inhibitor which is in Phase 3 clinical development that reduces elevated LDL-C levels in patients with hypercholesterolemia. It also focuses on the development of bempedoic acid in a fixed dose combination with ezetimibe, an LDL-C lowering therapy. Esperion is headquartered in Ann Arbor, Michigan, the US.

Esperion Therapeutics Inc (ESPR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Esperion Therapeutics Acquires 4WF from Cleveland Clinic 11
Venture Financing 12
Esperion Therapeutics Raises US$33 Million In Venture Financing 12
Esperion Therapeutics Raises US$1 Million In Venture Financing 14
Equity Offering 15
Esperion Therapeutics Prices Public Offering of Shares for USD152 Million 15
Esperion Therapeutics Raises USD201 Million in Public Offering of Shares 17
Esperion Therapeutics Raises USD98 Million in Public Offering of Shares 19
Esperion Therapeutics Completes Underwriters’ Exercise Of Over-Allotment Option For IPO For US$70 Million 21
Esperion Therapeutics Inc – Key Competitors 23
Esperion Therapeutics Inc – Key Employees 24
Esperion Therapeutics Inc – Locations And Subsidiaries 25
Head Office 25
Recent Developments 26
Financial Announcements 26
Nov 07, 2017: Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2017 Financial Results 26
Aug 08, 2017: Esperion Reports Second Quarter 2017 Financial Results 28
May 04, 2017: Esperion Reports First Quarter 2017 Financial Results 29
May 04, 2017: Esperion Therapeutics Q1 net loss up 30
Nov 03, 2016: Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Third Quarter 2016 Financial Results 31
Aug 04, 2016: Esperion Therapeutics Reports Second Quarter 2016 Financial Results 33
May 04, 2016: Esperion Therapeutics Reports First Quarter 2016 Financial Results 34
Feb 25, 2016: Esperion Therapeutics Provides Bempedoic Acid Development Program Update; Reports Fourth Quarter and Full Year 2015 Financial Results 35
Corporate Communications 37
Aug 11, 2017: Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 37
Product News 39
08/04/2016: Esperion Therapeutics Provides Bempedoic Acid Development Program Update 39
05/04/2016: Esperion Therapeutics Provides Bempedoic Acid Development Program Updates 40
Product Approvals 42
Jun 26, 2017: Esperion Announces FDA Confirmation of Regulatory Pathway to Approval for the Combination of Bempedoic Acid and Ezetimibe 42
Clinical Trials 43
Nov 06, 2017: Esperion Announces Initiation of Pivotal Phase 3 Study for the Bempedoic Acid / Ezetimibe Combination Pill 43
Aug 08, 2017: Esperion Announces Positive Top-Line Results From Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Plus Atorvastatin 44
Jun 28, 2016: Esperion Therapeutics Provides Clinical Development and Regulatory Update for Bempedoic Acid 45
Jan 13, 2016: Esperion Therapeutics Announces Initiation of Phase 3 Clinical Program With Long-Term Safety and Tolerability Study 47
Jan 12, 2016: Esperion Therapeutics Announces Initiation of Phase 2 Clinical Study of Bempedoic Acid in Patients Treated With High-Dose Statin Therapy 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49

List of Tables
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Esperion Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Esperion Therapeutics Acquires 4WF from Cleveland Clinic 11
Esperion Therapeutics Raises US$33 Million In Venture Financing 12
Esperion Therapeutics Raises US$1 Million In Venture Financing 14
Esperion Therapeutics Prices Public Offering of Shares for USD152 Million 15
Esperion Therapeutics Raises USD201 Million in Public Offering of Shares 17
Esperion Therapeutics Raises USD98 Million in Public Offering of Shares 19
Esperion Therapeutics Completes Underwriters' Exercise Of Over-Allotment Option For IPO For US$70 Million 21
Esperion Therapeutics Inc, Key Competitors 23
Esperion Therapeutics Inc, Key Employees 24

★海外企業調査レポート[Esperion Therapeutics Inc (ESPR)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • The Saudi Arabian Monetary Agency:企業の戦略的SWOT分析
    The Saudi Arabian Monetary Agency - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Petroleos Mexicanos:石油・ガス:M&Aディール及び事業提携情報
    Summary Petroleos Mexicanos (PEMEX) is a state-owned integrated oil and gas company. It operates across the value chain of oil and gas industry, from exploration and production to processing, logistics and marketing. PEMEX also produces and distributes a wide range of petrochemical products. The com …
  • Paranta Biosciences Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Paranta Biosciences Ltd (Paranta Biosciences) is a biopharmaceutical company that develops bio-therapeutics for the treatment of inflammatory and fibrotic diseases. The company develops product candidate PB01, a recombinant human follistatin-288 used for the treatment of cystic fibrosis lung …
  • Ocean Rig UDW Inc (ORIG):企業の財務・戦略的SWOT分析
    Summary Ocean Rig UDW Inc (Ocean Rig), formerly Primelead Shareholders Inc is an offshore drilling contractor that offers oilfield services. The company owns and operates 13 offshore ultra deepwater drilling units including ultra deepwater semi submersible drilling rigs, and ultra deepwater drillshi …
  • Zhuhai Holdings Investment Group Co Ltd:企業の戦略・SWOT・財務分析
    Zhuhai Holdings Investment Group Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Zhuhai Holdings Investment Group Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • OncoSec Medical Inc (ONCS):企業の財務・戦略的SWOT分析
    Summary OncoSec Medical Inc (OncoSec) is a biotechnology company. The company offers services to stimulate body’s immune system and attack cancer. Its lead candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor th …
  • Itamar Medical Ltd (ITMR)-製薬・医療分野:企業M&A・提携分析
    Summary Itamar Medical Ltd (Itamar Medical) is a medical device company that offers bio-medical technology products. The company develops, markets and distributes diagnostic medical devices. Its products include EndoPAT, a medical device for the diagnosis of endothelial dysfunction; and WatchPAT, a …
  • Curevac AG-製薬・医療分野:企業M&A・提携分析
    Summary Curevac AG (Curevac), formerly CureVac GmbH is a clinical stage biopharmaceutical company that develops RNA-based medicines. The company designs, develops and produces messenger RNA molecules for therapeutic and prophylactic vaccines in the fields of oncology and infectious diseases. Its RNA …
  • Quidel Corp (QDEL):企業の財務・戦略的SWOT分析
    Quidel Corp (QDEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • ENGlobal Corp (ENG):石油・ガス:M&Aディール及び事業提携情報
    Summary ENGlobal Corp (ENGlobal) is a specialty engineering services firm that offers oilfield automation solutions. The firm’s services comprise automation integration, engineering and construction, subsea controls and integration, and automation engineering and design services. Its automation inte …
  • Impellam Group plc (IPEL):企業の財務・戦略的SWOT分析
    Impellam Group plc (IPEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Mechel:企業の戦略・SWOT・財務情報
    Mechel - Strategy, SWOT and Corporate Finance Report Summary Mechel - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Denso Corporation:企業の戦略・SWOT・財務分析
    Denso Corporation - Strategy, SWOT and Corporate Finance Report Summary Denso Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Breathe Technologies Inc:医療機器:M&Aディール及び事業提携情報
    Summary Breathe Technologies Inc (Breathe Technologies) is a home health care service provider that manufactures and develops innovative medical technologies for patients with respiratory insufficiency and neuromuscular diseases. The company offers research, development and production of new therape …
  • Peptilogics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Peptilogics Inc (Peptilogics) is an early-stage biotechnology company that develops novel peptide therapeutics. The company’s antibiotics address the epidemic of multidrug-resistant bacterial infections. Its products portfolio includes engineered Cationic Antibiotic Peptides (eCAP) technolog …
  • Indena SpA:企業の戦略的SWOT分析
    Indena SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Jiuzhitang Co Ltd (000989):製薬・医療:M&Aディール及び事業提携情報
    Summary Jiuzhitang Co Ltd (Jiuzhitang), formerly Labor Jiuzhitang Pharmacy, is a Chinese medicine manufacturing company. The company offers products such as shuxuetong injection, lujiao granule, liuwei dihuang wan pills, zuguang power, siqikang injection, luo hua zi zhu tablets, compound jiangzhi ta …
  • Servest Group Ltd:企業の戦略的SWOT分析
    Servest Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • BioScrip Inc (BIOS):企業の財務・戦略的SWOT分析
    BioScrip Inc (BIOS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Globus Medical Inc (GMED):企業の財務・戦略的SWOT分析
    Globus Medical Inc (GMED) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆